SCHEMBL4395732

SCHEMBL4395732

Oc1ccc(Cl)c2ccc(Cc3ccc4c(Cl)ccc(O)c4n3)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
KDM4E B2RXH2 2/20 0.49
LMNA P02545 2/20 0.49
HSP90AA1 P07900 2/20 0.49
BRD4 O60885 1/20 0.49
METAP2 P50579 1/20 0.49
METAP1 P53582 1/20 0.49
PIM1 P11309 1/20 0.47
KMT2A Q03164 2/20 0.38
OPRK1 P41145 1/20 0.38
CYP3A4 P08684 2/20 0.34
MAPK1 P28482 1/20 0.34
PDE10A Q9Y233 4/20 0.34
NQO2 P16083 1/20 0.33
CCR1 P32246 1/20 0.32
CTSB P07858 1/20 0.32
CTSH P09668 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
HSD17B1 P14061 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4393540 0.89 MAPT (0.49) MAPTKDM4ELMNAHSP90AA1BRD4
SCHEMBL12834067 0.88 KDM4E (0.40) MAPTKDM4ELMNAHSP90AA1BRD4
SCHEMBL28250159 0.87 CCR1 (0.48) MAPTKDM4ELMNAHSP90AA1BRD4
SCHEMBL5943583 0.84 OPRK1 (0.42) KDM4ELMNABRD4KMT2AOPRK1
SCHEMBL325434 0.82 OPRK1 (0.41) KDM4ELMNABRD4KMT2AOPRK1
SCHEMBL16106500 0.79 KDM4E (0.41) MAPTKDM4ELMNAHSP90AA1BRD4
SCHEMBL3984759 0.79 MAPT (0.53) MAPTKDM4ELMNAHSP90AA1BRD4
SCHEMBL24634694 0.77 KDM4E (0.39) MAPTKDM4ELMNAHSP90AA1BRD4
SCHEMBL9871905 0.76 PIM1 (0.51) MAPTKDM4ELMNAHSP90AA1BRD4
SCHEMBL7692195 0.76 KMT2A (0.67) MAPTKDM4ELMNAHSP90AA1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US claimed
EP-1919894-B1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF PALUMED SA (FR) 2014-10-08 EP disclosed
US-8324196-B2 Polyquinoline derivatives and the therapeutic use thereof PALUMED S.A. (FR) 2012-12-04 US disclosed
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-11-01 US disclosed
US-8247396-B2 Polyquinoline derivatives and therapeutic use thereof PALUMED S.A. (FR) 2012-08-21 US disclosed
US-8247396-B2 Polyquinoline derivatives and therapeutic use thereof PALUMED S.A. (FR) 2012-08-21 US disclosed
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF HTT, APP, PSEN1 MAPT 14/4885KDM4E 4293/4885LMNA 1091/4885
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF HTT, UBQLN2, UBQLN1 MAPT 235/4885KDM4E 3878/4885LMNA 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.